Jim Cramer: Buy Acadia, Amazon, and These 3 Stocks

Jim Cramer made the following calls on October 1st, 2013. What do you think about his picks?

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on May 23, 2013. The stock’s 52-week high is $28.38, and its 52-week low is $1.80. Cramer gave a positive review of Acadia Pharmaceuticals, a biotech company that he believes could gain value independent of the budget debate in Washington. Acadia specializes in creating drugs to treat neurological and nervous system disorders, with their pimavanserin drug to treat Parkinson’s psychosis currently in phase III development.

ACAD 20131002

Amazon.com Inc. (NASDAQ:AMZN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 26, 2013. The stock’s 52-week high is $321.00, and its 52-week low is $218.18. Cramer was a fan of Amazon, the online retail giant, claiming that they are having a great quarter. He did warn that the stock is already trading at a high multiple, meaning that it is not a cheap company to buy in to at the current point in time.

AMZN 20131002

Celldex Therapeutics, Inc. (NASDAQ:CLDX): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 1, 2013. The stock’s 52-week high is $37.98, and its 52-week low is $5.02. Cramer expressed optimism about Celldex, a biotech company that has posted a tremendous increase in its stock value over both the previous 1-month and 6-month time periods.

CLDX 20131002

Clovis Oncology Inc (NASDAQ:CLVS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Sell on June 14, 2013. The stock’s 52-week high is $86.29, and its 52-week low is $11.19. Cramer reversed his opinion on Clovis Oncology, including it in a discussion of smaller biotech companies that have a lot of poise over the coming months. Of course, Cramer was mindful of the risks inherent in such companies as well; Clovis has recently seen a downward spike in its share price when it was announced that Credit Suisse was unable to find any potential buyers for the company.

CLVS 20131002

Don’t Miss: ‘Catching Fire’ Is Already Selling Tickets at Fierce Pace.